Shrimp Disease Diagnostics Market Size, Share, and Growth Forecast 2026 - 2033

The global shrimp disease diagnostics market size is expected to be valued at US$ 586.5 million in 2026 and projected to reach US$ 1,248.8 million by 2033, growing at a CAGR of 11.4% between 2026 and 2033.

Rising economic losses caused by recurring viral and bacterial shrimp diseases across major aquaculture-producing nations are the primary force propelling this expansion, as farmers and processors increasingly adopt early disease detection to safeguard production yields.

The Food and Agriculture Organization continues to highlight disease outbreaks as a leading cause of shrimp aquaculture production losses globally, while growing government biosecurity mandates and rising export quality certification requirements are simultaneously accelerating adoption of molecular and assay-based diagnostic testing across shrimp farming operations worldwide.

Drivers - Growing Economic Losses from Recurring Viral Shrimp Disease Outbreaks

Recurring outbreaks of viral and bacterial shrimp diseases continue to inflict substantial economic losses across global aquaculture production, creating strong demand for reliable diagnostic solutions. The Food and Agriculture Organization has repeatedly identified disease outbreaks, including White Spot Syndrome Virus and Acute Hepatopancreatic Necrosis Disease, as major contributors to reduced shrimp yields across Asia and Latin America. Given the rapid transmissibility of these pathogens within densely stocked ponds, early detection through diagnostic testing has become essential for containing outbreaks before they spread across entire farming operations.

As shrimp farmers increasingly recognize the cost advantage of preventive testing over catastrophic crop losses, adoption of routine diagnostic screening continues to expand across commercial hatcheries and grow-out farms, reinforcing sustained demand for both rapid and assay-based diagnostic kits throughout the global shrimp aquaculture industry.

Growing Government Biosecurity Mandates and Export Certification Requirements

Strengthening government biosecurity regulations and export quality certification requirements are significantly reinforcing shrimp disease diagnostics adoption worldwide. Regulatory bodies, including the World Organization for Animal Health, maintain detailed reporting and testing protocols for notifiable shrimp diseases, compelling exporting nations to implement systematic diagnostic screening programs to maintain international trade access.

Major shrimp-exporting countries across Asia have introduced mandatory pre-export disease testing requirements to comply with importing nation biosecurity standards, particularly for markets in North America and Europe. This regulatory alignment is prompting hatcheries, processors, and export-oriented farming operations to integrate routine diagnostic testing into standard operating procedures, creating consistent, recurring demand for validated shrimp disease diagnostic kits and testing services across the global aquaculture supply chain.

Restraints - Limited Diagnostic Infrastructure in Smallholder Farming Regions

A significant share of global shrimp production originates from smallholder and semi-intensive farming operations that lack access to laboratory infrastructure or trained diagnostic personnel. According to the Food and Agriculture Organization, small-scale aquaculture producers across many developing regions continue to rely on visual disease symptom identification rather than confirmatory laboratory testing. This infrastructure gap limits diagnostic kit penetration in high-disease-risk regions where testing could deliver the greatest preventive value, constraining overall market growth despite strong underlying demand for improved shrimp health monitoring.

High Cost of Advanced Molecular Diagnostic Testing

Advanced molecular diagnostic techniques capable of detecting low-level pathogen loads require specialized equipment and reagents that remain cost-prohibitive for many smaller aquaculture operations. Assay-based testing, while more sensitive than rapid testing kits, involves higher per-sample costs and longer turnaround times requiring centralized laboratory processing. This cost sensitivity is particularly pronounced among small and medium-sized shrimp farms operating on thin margins, where diagnostic testing budgets often compete directly with feed and infrastructure expenditure, thereby moderating broader market penetration across price-sensitive farming segments globally.

Opportunities - Rising Adoption of Portable Rapid Testing Kits Among Farm-Level Users

Growing demand for portable, easy-to-use rapid testing kits presents a significant opportunity for diagnostic manufacturers targeting farm-level end users. Unlike laboratory-based assay testing, rapid testing kits enable on-site disease screening without requiring specialized equipment or extensive technical training, making them particularly attractive to smallholder farmers and hatchery operators seeking immediate results. Companies such as GeneReach Biotechnology Corp. and REAGEN LLC have expanded portable diagnostic kit offerings designed for field-level shrimp health monitoring.

As biosecurity awareness continues to grow across emerging aquaculture-producing regions, rapid testing kits are projected to register the fastest growth among all kit categories through 2033, offering manufacturers a meaningful opportunity to expand market reach among cost-sensitive, decentralized farming operations that previously lacked practical access to diagnostic testing.

Expanding Aquaculture Production Across Latin America

Rapid expansion of shrimp aquaculture production across Latin America presents a substantial opportunity for diagnostic solution providers. Countries in the region have significantly scaled shrimp farming output in recent years, supported by favorable growing conditions and rising global demand for farmed shrimp exports, according to data referenced by the Food and Agriculture Organization. As production intensifies, disease management has become a growing priority for regional farmers seeking to protect export revenue and maintain international biosecurity compliance.

Diagnostic companies expanding distribution networks and localized technical support across Ecuador and neighboring producing nations are well positioned to capture this accelerating regional demand, particularly as Latin America is projected to register the fastest regional growth in shrimp disease diagnostics adoption through the forecast period.

Disease Analysis

White Spot Syndrome Virus represents the leading disease segment, accounting for an estimated 32% share of diagnostic testing demand in 2026. This dominance reflects the virus's status as one of the most economically destructive shrimp pathogens globally, capable of causing near-total pond mortality within days of outbreak onset.

The World Organisation for Animal Health classifies White Spot Syndrome Virus as a notifiable aquatic disease, mandating systematic surveillance and testing across major shrimp-producing nations. This regulatory classification, combined with the virus's high transmissibility and long environmental persistence, continues to drive routine diagnostic screening across hatcheries and grow-out farms. Early Mortality Syndrome and Acute Hepatopancreatic Necrosis Disease are projected to register the fastest growth through 2033, driven by the disease's continued geographic spread across Asian and Latin American shrimp farming regions and growing farmer awareness of its early-stage detectability through diagnostic testing.

Kits Analysis

Assay based kits dominate the kits segment, commanding an estimated 69% share of the market in 2026. Their leading position reflects the superior sensitivity and specificity these testing formats offer compared to rapid testing alternatives, enabling accurate detection of low-level pathogen loads critical for early-stage disease identification.

Export-oriented hatcheries and processing facilities particularly favor assay-based testing given stringent international biosecurity certification requirements referenced by the World Organisation for Animal Health. This reliability advantage has cemented assay-based kits as the preferred choice among laboratories and large-scale commercial farming operations. Rapid testing kits are projected to register the fastest growth through 2033, propelled by rising farm-level demand for immediate, on-site disease screening that does not require centralized laboratory processing or specialized technical expertise.

North America Shrimp Disease Diagnostics Market Trends and Insights

North America accounted for approximately 11.5% of the global shrimp disease diagnostics market in 2026, supported by expanding biosecure shrimp aquaculture and stringent aquatic animal health surveillance. The region imported more than 900,000 metric tons of shrimp annually, making disease screening and traceability essential for food safety and biosecurity.

The U.S. Department of Agriculture (USDA) and NOAA Fisheries continue to strengthen aquatic animal disease monitoring programs, while investments in indoor recirculating aquaculture systems (RAS) have increased the need for routine pathogen testing. Growing concerns over transboundary diseases such as White Spot Syndrome Virus (WSSV) and EMS/AHPND, combined with rising adoption of PCR-based diagnostics in hatcheries and import inspection laboratories, continue to support steady market expansion across North America.

U.S. Shrimp Disease Diagnostics Market Size

The United States accounted for the largest share of the North American shrimp disease diagnostics market, supported by its extensive seafood import network and growing domestic shrimp farming industry. The country imported over 800,000 metric tons of shrimp annually, making it one of the world's largest shrimp importers and reinforcing demand for rigorous pathogen screening. Increasing investment in land-based shrimp farming and recirculating aquaculture systems has further accelerated the adoption of molecular diagnostic technologies for routine disease surveillance. Federal oversight by the USDA, FDA, and NOAA Fisheries continues to strengthen biosecurity protocols, supporting sustained demand for shrimp disease diagnostic kits and laboratory testing services.

Europe Shrimp Disease Diagnostics Market Trends and Insights

Europe represented approximately 7.8% of the global shrimp disease diagnostics market in 2026, driven primarily by seafood import surveillance rather than domestic shrimp farming. The European Union imported more than 900,000 metric tons of shrimp and prawns annually, making biosecurity testing a critical component of import compliance. Regulations governing aquatic animal health and food safety continue to encourage routine pathogen screening for imported shrimp.

Growing research activities focused on aquatic diseases and increasing collaboration between veterinary laboratories and academic institutions further support diagnostic demand. The expansion of molecular testing methods, including PCR and qPCR, across reference laboratories has strengthened Europe's disease surveillance capabilities while ensuring compliance with stringent import and animal health regulations.

Germany Shrimp Disease Diagnostics Market Size

Germany held a significant share of Europe's shrimp disease diagnostics market due to its position as one of the region's largest seafood importers and distributors. The country serves as a major entry point for imported shrimp destined for European markets, requiring strict biosecurity and food safety compliance.

National veterinary laboratories and research institutions continue to expand aquatic pathogen surveillance using advanced molecular diagnostic technologies. Increasing emphasis on traceability and compliance with European aquatic animal health regulations has strengthened demand for routine shrimp disease testing. These factors continue to support Germany's leading contribution to the regional shrimp disease diagnostics market.

U.K. Shrimp Disease Diagnostics Market Size

The United Kingdom maintained a notable share of the European shrimp disease diagnostics market, supported by substantial seafood imports and stringent import inspection requirements. Government agencies continue to enforce aquatic animal health regulations aimed at preventing the introduction of transboundary diseases through imported seafood.

Growing investment in aquatic veterinary research and disease surveillance programs has accelerated the adoption of PCR-based diagnostic methods. Increasing consumer demand for traceable and sustainably sourced seafood has further encouraged importers and distributors to implement comprehensive pathogen testing protocols, reinforcing steady growth in the country's shrimp disease diagnostics market.

France Shrimp Disease Diagnostics Market Size

France contributed a steady share to the European shrimp disease diagnostics market through its established seafood import infrastructure and strong aquatic research ecosystem. The country imports significant volumes of shrimp each year, supporting continuous demand for pathogen detection and biosecurity screening. French research institutes and veterinary laboratories actively participate in aquatic animal health monitoring and diagnostic method development. Increasing regulatory focus on seafood traceability and import safety has promoted wider adoption of molecular diagnostic technologies for shrimp disease detection. These initiatives continue to support stable demand for shrimp disease diagnostic kits and laboratory services across France.

Asia-Pacific Shrimp Disease Diagnostics Market Trends and Insights

Asia-Pacific dominated the global shrimp disease diagnostics market with approximately 58.7% market share in 2026, reflecting its position as the world's largest shrimp-producing and exporting region. Countries including China, India, Vietnam, Indonesia, and Thailand account for the majority of global farmed shrimp production, creating substantial demand for routine disease surveillance.

India and Ecuador together exported well over 1 million metric tons of shrimp annually, while China remained one of the largest aquaculture producers worldwide. Frequent outbreaks of WSSV, EMS/AHPND, and EHP have accelerated government-led surveillance programs and hatchery screening initiatives. Increasing adoption of PCR, qPCR, and rapid diagnostic kits, supported by export certification requirements and strengthened biosecurity regulations, continues to drive regional market growth.

India Shrimp Disease Diagnostics Market Size

India accounted for a substantial share of the Asia-Pacific shrimp disease diagnostics market, supported by its status as one of the world's largest shrimp exporters. The country exported more than 700,000 metric tons of frozen shrimp annually, making disease-free certification essential for international trade. Government agencies have expanded aquatic animal health surveillance and hatchery biosecurity programs to reduce disease outbreaks affecting export production.

Increasing adoption of PCR-based pathogen detection across hatcheries, farms, and diagnostic laboratories has strengthened routine surveillance for WSSV, EMS/AHPND, and EHP, supporting continued growth in India's shrimp disease diagnostics market.

Japan Shrimp Disease Diagnostics Market Size

Japan maintained a steady share of the Asia-Pacific shrimp disease diagnostics market due to its stringent seafood import inspection framework and advanced laboratory infrastructure. As one of the world's major shrimp-importing nations, Japan relies heavily on pathogen screening to ensure food safety and aquatic biosecurity. Government-supported aquatic animal health research and widespread adoption of molecular diagnostic technologies continue to strengthen surveillance capabilities. Increasing emphasis on traceability and disease-free seafood imports has reinforced demand for advanced shrimp disease diagnostic kits and laboratory testing services throughout the country.

Southeast Asia Shrimp Disease Diagnostics Market Size

Southeast Asia represented a major portion of the Asia-Pacific shrimp disease diagnostics market, driven by intensive shrimp farming in Vietnam, Thailand, Indonesia, and Malaysia. The region accounts for a significant share of global farmed shrimp exports, making disease management critical for maintaining production and export competitiveness. Governments have strengthened surveillance programs for WSSV, EMS/AHPND, and EHP while encouraging wider adoption of PCR and rapid diagnostic testing at hatcheries and farms. Expanding export certification requirements and ongoing investments in aquaculture biosecurity continue to accelerate demand for shrimp disease diagnostics across Southeast Asia.

The global shrimp disease diagnostics market is moderately fragmented, comprising a mix of established diagnostic instrument manufacturers and specialized regional kit developers. Leading players such as Thermo Fisher Scientific, GeneReach Biotechnology Corp., and Bio-Rad Laboratories, Inc. are prioritizing rapid testing kit innovation, expanded pathogen detection panels, and strengthened distribution networks across major shrimp-producing regions to differentiate their offerings. Strategic emphasis on research and development, localized technical support, and regulatory compliance validation remains central to competitive positioning.

Regional manufacturers are increasingly targeting cost-sensitive farming segments through affordable rapid testing formats, while established players continue defending share through broad pathogen panel coverage and long-standing relationships with hatcheries and export-oriented processing facilities.

Key Developments:

• January 2025: Seek Labs announced that its SeekIt WSSV Field Kit was validated in studies by Florida Atlantic University’s Aquatic Animal Health Lab (AAHL) and ShrimpVet Laboratory as an accurate and cost-effective tool for detecting White Spot Syndrome Virus (WSSV) in shrimp. The kit detected the virus as early as 24 hours after infection, matching the accuracy of standard qPCR lab methods without requiring specialized equipment or training.
• August 2024: Bio-X Diagnostics and BioChek announced a strategic partnership to strengthen their veterinary and aquaculture diagnostic offerings. Under the agreement, the companies combined their expertise in diagnostic assay development, manufacturing, and global distribution to expand access to high-quality disease detection solutions.
• January 2024: Genics announced the launch of Shrimp MultiPath 2.0, a breakthrough diagnostic tool that detects 18 shrimp pathogens with a single test. The new technology set a new industry standard by offering shrimp farmers a cost-effective and comprehensive solution for pathogen detection, enhancing biosecurity and animal health management.